Clinical Data Spyre deprioritises arthritis drug after Phase 2 results PharmaphorumSpyre Therapeutics' hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road.Immunology & InflammationRead full story pharminent August 26, 2026 (Last updated: August 26, 2026) Pharmaphorum Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road. Immunology & Inflammation Read full story Post navigation Previous: Metsera backers establish new biotech armed with China-licensed immunology assetNext: FDA Approves Revolution Medicines’ Rasonque, First RAS(ON) Inhibitor for Metastatic Pancreatic Cancer Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026